VivoSim Labs (FRA:4OR) EPS without NRI: €1.83 (TTM As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
39 GF Score
Price €3.49
GF Value €8.71
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs EPS without NRI?

VivoSim Labs FRA:4OR 39 EPS without NRI is €1.83 as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.71. The stock has 4 warning signs investors should review. Among 1,172 Biotechnology companies, VivoSim Labs ranks better than 58.53% on this metric.

VivoSim Labs's earnings per share without non-recurring items for the three months ended in Dec. 2025 was €-0.88. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €1.83.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 23.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for VivoSim Labs's EPS without NRI or its related term are showing as below:

FRA:4OR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -533.4   Med: 13   Max: 34
Current: 23.5

During the past 13 years, VivoSim Labs's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 34.00% per year. The lowest was -533.40% per year. And the median was 13.00% per year.

FRA:4OR's 3-Year EPS without NRI Growth Rate is ranked better than
58.53% of 1172 companies
in the Biotechnology industry
Industry Median: 16.8 vs FRA:4OR: 23.50

VivoSim Labs's EPS (Diluted) for the three months ended in Dec. 2025 was €-0.88. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €1.83.

VivoSim Labs's EPS (Basic) for the three months ended in Dec. 2025 was €-0.88. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €1.83.


VivoSim Labs  (FRA:4OR) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


VivoSim Labs EPS without NRI Related Terms


VivoSim Labs EPS without NRI Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs EPS without NRI Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.57 -14.38 -22.22 -17.72 -6.57

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.18 4.53 -0.99 -0.84 -0.88

FRA:4OR vs SLXN, CDT, CLDI: EPS without NRI Comparison

For the Biotechnology subindustry, VivoSim Labs's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's PE Ratio without NRI falls into.


FRA:4OR
39GF Score
VivoSim Labs Inc FRA:4OR
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €1.83 mean?
VivoSim Labs (FRA:4OR) has a EPS without NRI of €1.83 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #486 out of 1172 companies in the Biotechnology industry, placing it in the top 41.5%.
Is VivoSim Labs' EPS without NRI too high?
VivoSim Labs' current EPS without NRI is €1.83. Based on the distribution chart, VivoSim Labs ranks #486 out of 1172 companies in the Biotechnology industry, which is above the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' EPS without NRI compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #486 out of 1172 companies for EPS without NRI. This puts VivoSim Labs in the upper half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current EPS without NRI is €1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current EPS without NRI of €1.83. The stock's GF Value™ is €8.71, compared to a current price of €3.49 — trading 59.9% below its estimated fair value. The current EPS without NRI is €1.83. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current EPS without NRI is €1.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 59.9% below its estimated GF Value™ of €8.71.

Key valuation signals for FRA:4OR:

  • EPS without NRI: €1.83
  • GF Value™: €8.71 vs. price of €3.49 (59.9% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score

Get the complete analysis for FRA:4OR

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€8.71
GF Value